Showing results (11-20 of 1,815) with videos related to

Sort By:
Pageof 182
Contemporary Clinical Trials|November 27, 2020
Sample size re-estimation in adaptive enrichment designRuitao Lin, Zhao Yang, Ying Yuan, et al.
Statistical Methods in Medical Research|April 4, 2024
A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studiesFeng Tian, Ruitao Lin, Li Wang, et al.
International Journal of Epidemiology|May 20, 2025
Sample-size determination for decentralized clinical trialsFeng Tian, Ruitao Lin, Suyu Liu, et al.
Statistics in Biopharmaceutical Research|May 5, 2025
Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination TrialsMengyi Lu, Jingyi Zhang, Ying Yuan, et al.
Statistics in Medicine|March 2, 2021
uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trialsHaolun Shi, Jiguo Cao, Ying Yuan, et al.
Statistics in Medicine|May 15, 2024
Design and sample size determination for multiple-dose randomized phase II trials for dose optimizationPeng Yang, Daniel Li, Ruitao Lin, et al.
JCO Precision Oncology|December 7, 2020
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesRuitao Lin, Yanhong Zhou, Fangrong Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2018
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I TrialsYing Yuan, Ruitao Lin, Daniel Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2026
Generalised pairwise comparisons in dose-optimisation oncology trials: beyond safety to multi-outcome dose selectionEmily Alger, Ruitao Lin, J Jack Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Practical Considerations for Using the TITE-BOIN Design to Handle Late-onset Toxicity or Fast Accrual in Phase I TrialsKai Chen, Ting-Yu Chen, Yiming Zhang, et al.
Pageof 182